drugset / Trial / NCT06764771
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
Timeline
- Start
- 2025-03-25
- Primary completion
- 2027-10-15
- Completion
- 2027-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | — | — |
| Subject | BMS-986488 | Unknown | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |